Diabetes is one of the fastest growing diseases worldwide, projected to affect 693 million
adults by 2045. Devastating macrovascular complications (cardiovascular disease) and …

The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …

Abstract Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic, and
viral infections. The severe acute respiratory syndrome (SARS)-CoV-2 (also referred to as …

Background Nonalcoholic steatohepatitis (NASH) is a common disease that is associated
with increased morbidity and mortality, but treatment options are limited. The efficacy and …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Type 2 diabetes mellitus (T2DM) continues to be a substantial medical problem due to its
increasing global prevalence and because chronic hyperglycemic states are closely linked …

Obesity contributes to reduced life expectancy, impaired quality of life, and disabilities,
mainly in those individuals who develop cardiovascular diseases, type 2 diabetes …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Abstract The Committee of Clinical Practice Guidelines of the Korean Diabetes Association
(KDA) updated the previous clinical practice guidelines for Korean adults with diabetes and …